How Much Does Actos (Pioglitazone) Cost in Minnesota in 2026?

Minnesota Retail Pricing: Generic vs. Brand Actos

The average cash-pay price for generic pioglitazone 30 mg across Minnesota retail pharmacies sits at approximately $15 per month in 2026. Brand-name Actos from Takeda lists at roughly $60 per month, a four-fold premium that few patients need to pay given identical bioequivalence between the generic and branded product.

Pioglitazone lost patent exclusivity in 2012, and the resulting competition among generic manufacturers has driven prices well below most other oral diabetes medications. For context, the FDA Orange Book lists more than a dozen approved generic pioglitazone formulations. That level of manufacturer competition explains why Minnesota pharmacies can offer the drug at prices competitive with over-the-counter supplements.

Pricing does vary by pharmacy. Large chain pharmacies in Minneapolis-St. Paul metro areas tend to price generic pioglitazone between $10 and $18 for a 30-day supply. Rural pharmacies in Greater Minnesota may charge slightly more due to distributor markup differences, though the gap rarely exceeds $5. Warehouse clubs like Costco and Sam's Club sometimes list 90-day supplies for under $30, which can bring the effective monthly cost below $10 for patients willing to fill quarterly.

The price advantage of generic pioglitazone becomes even more apparent when compared to newer diabetes medications. A month of brand-name semaglutide (Ozempic) can exceed $900 without insurance, and even tirzepatide (Mounjaro) runs above $1,000 at list price. Pioglitazone occupies a different pharmacological class (thiazolidinedione rather than GLP-1 receptor agonist), but for patients whose primary need is insulin sensitization, it remains one of the most affordable prescription options available [1].

Minnesota Medicaid Coverage for Pioglitazone

Minnesota Medical Assistance (the state's Medicaid program) covers pioglitazone, but requires prior authorization before dispensing. The PA requirement means a prescriber must submit clinical documentation showing the medication is medically necessary for the patient's condition.

In practice, PA approval for pioglitazone in Minnesota Medicaid is straightforward for patients with a confirmed type 2 diabetes diagnosis who have tried or cannot tolerate metformin. The American Diabetes Association Standards of Care position thiazolidinediones as a second- or third-line option after metformin, and Minnesota Medicaid formulary committees generally align with ADA guidance [2].

For off-label use in NASH (now termed MASH), PA approval is less predictable. The PIVENS trial (N=247) demonstrated that pioglitazone 30 mg significantly improved hepatic steatosis and lobular inflammation compared to placebo in non-diabetic patients with biopsy-proven NASH over 96 weeks [3]. Despite this evidence, Minnesota Medicaid has not formally added NASH as a covered indication. Prescribers seeking off-label coverage should include PIVENS trial data and liver biopsy results in their PA submissions.

MinnesotaCare, the state's subsidized health plan for lower-income residents who don't qualify for full Medicaid, follows the same formulary. Copays under both programs typically range from $1 to $3 for generic medications, making pioglitazone effectively free for enrolled patients once PA clears.

Commercial Insurance Coverage in Minnesota

Most commercial health plans sold in Minnesota cover generic pioglitazone on their preferred formulary tiers. The state's largest insurers, including Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, and UCare, all list generic pioglitazone on Tier 1 or Tier 2 of their 2026 formularies.

Tier 1 placement means the lowest copay bracket, which ranges from $0 to $15 per fill depending on the specific plan. Some high-deductible health plans (HDHPs) popular with Minnesota employers require patients to pay full cash price until meeting their deductible, but at $15 per month for generic pioglitazone, the out-of-pocket burden remains minimal even in those arrangements.

Patients enrolled in Medicare Part D plans in Minnesota will find pioglitazone covered under most plan formularies. The 2026 Medicare Part D redesign caps annual out-of-pocket drug spending at $2,000, a threshold that pioglitazone alone would never approach given its low cost [4]. Medicare Advantage plans from the major Minnesota carriers generally mirror Part D formulary placement.

Brand-name Actos rarely appears on preferred formulary tiers. Insurers have little incentive to cover the brand when a bioequivalent generic costs 75% less. Patients or prescribers requesting brand-only dispensing should expect a non-preferred tier copay or a step therapy requirement to try generic first.

Compounded Pioglitazone in Minnesota

Compounded pioglitazone is legally available in Minnesota through licensed 503A pharmacies. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding based on a valid prescription [5].

Why would a patient choose compounded pioglitazone? The most common reason is dose customization. FDA-approved pioglitazone tablets come in 15 mg, 30 mg, and 45 mg strengths. A prescriber targeting a specific dose between those increments (say, 22.5 mg for a patient who responds to 15 mg but needs slightly more) would need a compounding pharmacy to prepare that formulation. Dysphagia patients who cannot swallow tablets may also benefit from compounded liquid suspensions.

Minnesota's Board of Pharmacy regulates 503A compounding pharmacies and requires them to meet USP <795> standards for non-sterile preparations. Several compounding pharmacies in the Twin Cities metro area and in Rochester (near Mayo Clinic) offer pioglitazone compounding services. Pricing varies, but because pioglitazone's active pharmaceutical ingredient (API) is inexpensive and widely available, compounded formulations can cost as little as the generic tablet price, and sometimes less for cash-pay patients ordering in bulk.

One important distinction: 503B outsourcing facilities (which compound in bulk without patient-specific prescriptions) do not commonly stock pioglitazone because the generic tablet market is already saturated with affordable options. Most compounded pioglitazone in Minnesota comes from 503A pharmacies filling individual prescriptions.

Telehealth Prescribing of Pioglitazone in Minnesota

Minnesota permits telehealth prescribing of pioglitazone with no geographic or setting restrictions for non-controlled substances. Pioglitazone is not a controlled substance under either federal or Minnesota law, so any provider licensed in Minnesota can prescribe it via a synchronous audio-video visit or, in some cases, an asynchronous evaluation.

The Minnesota Telehealth Act, codified at Minnesota Statutes Section 62A.673, requires health plans to cover telehealth services on par with in-person visits [6]. This means a patient who sees an endocrinologist or primary care provider via telehealth for a pioglitazone prescription should pay the same copay or coinsurance as they would for an office visit. The Endocrine Society's 2024 clinical practice guidelines note that thiazolidinediones like pioglitazone require periodic monitoring of liver function and signs of fluid retention, but these lab orders and assessments can be managed remotely with local lab draws [7].

Several national telehealth platforms now serve Minnesota patients for diabetes management, including those specializing in metabolic health. Patients in rural Minnesota counties where endocrinology access is limited can particularly benefit from telehealth prescribing pathways. Wait times for in-person endocrinology appointments in parts of northern and western Minnesota can stretch beyond eight weeks, while telehealth platforms typically offer appointments within days.

Savings Programs and Discount Cards

Multiple savings pathways can reduce pioglitazone costs for Minnesota residents, even below the already-low $15 per month generic price.

Pharmacy discount cards. Programs like GoodRx, RxSaver, and SingleCare negotiate rates with pharmacy benefit managers and can drop generic pioglitazone prices to $4 to $8 per month at participating Minnesota pharmacies. These cards work for uninsured patients and can sometimes beat insurance copays. They cannot be combined with government insurance (Medicaid, Medicare), but patients with commercial insurance may compare their copay against the discount card price and use whichever is lower.

Manufacturer programs. Takeda's patient assistance program covers brand Actos for uninsured patients who meet income thresholds (generally below 300% of the federal poverty level). Given that generic pioglitazone is cheaper than most manufacturer assistance programs can deliver, this pathway is primarily relevant for the small number of patients with documented brand-medically-necessary situations.

$4 generic lists. Several Minnesota pharmacy chains include pioglitazone on their $4 generic medication lists for a 30-day supply, and $10 for a 90-day supply. Walmart, Hy-Vee, and Costco all maintain such programs in their Minnesota locations. These prices require no insurance, no discount card, and no enrollment. Just ask the pharmacist.

340B pricing. Patients who receive care at 340B-eligible facilities (including Hennepin Healthcare, several Federally Qualified Health Centers across Minnesota, and some rural critical access hospitals) may access pioglitazone at even lower prices. The 340B Drug Pricing Program requires manufacturers to sell outpatient drugs to eligible facilities at significant discounts, and those savings can be passed to patients [8].

Clinical Considerations Affecting Cost Decisions

The cost conversation around pioglitazone cannot be separated from clinical decision-making. Pioglitazone's primary mechanism, activation of PPARγ receptors to improve insulin sensitivity, makes it particularly useful in patients with significant insulin resistance, a population that overlaps heavily with those who have NAFLD/NASH.

The PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis) published in the New England Journal of Medicine found that pioglitazone 30 mg daily achieved resolution of NASH in 47% of treated patients versus 21% in the placebo group (P<0.001) over 96 weeks [3]. This finding has driven off-label prescribing that continues to grow.

Weight gain is the most commonly cited side effect influencing patient decisions. In PIVENS, pioglitazone-treated patients gained a mean of 4.7 kg over 96 weeks [3]. The FDA prescribing label also warns about fluid retention, which can exacerbate heart failure in susceptible patients [9]. Dr. Kenneth Cusi, Chief of the Division of Endocrinology at the University of Florida and a leading researcher on pioglitazone in NASH, has stated: "Pioglitazone remains the only drug with level A evidence for NASH resolution in patients with and without diabetes. The weight gain is real but manageable, and the cardiovascular benefits in the PROactive trial add to its value proposition" [10].

The PROactive trial (N=5,238) demonstrated that pioglitazone reduced the composite of all-cause mortality, non-fatal myocardial infarction, and stroke by 16% in patients with type 2 diabetes and macrovascular disease (HR 0.84, 95% CI 0.72-0.98, P=0.027) [11]. For Minnesota patients weighing pioglitazone against newer, more expensive alternatives, this cardiovascular benefit at a fraction of the cost is a data point worth discussing with their prescriber.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on type 2 diabetes management lists pioglitazone as a recommended option when insulin sensitization is the primary therapeutic goal, particularly in patients with concurrent NAFLD [12].

How Minnesota Compares to Neighboring States

Generic pioglitazone pricing in Minnesota tracks closely with neighboring Upper Midwest states. Wisconsin, Iowa, and the Dakotas all show average cash-pay prices in the $12 to $18 range for a 30-day supply of generic pioglitazone 30 mg. Minnesota's pricing falls in the middle of that band.

Medicaid coverage differs more meaningfully. Wisconsin Medicaid covers pioglitazone without prior authorization for type 2 diabetes, placing it on the preferred drug list. Iowa Medicaid also requires PA, similar to Minnesota. North Dakota Medicaid covers pioglitazone as a non-preferred brand requiring PA and step therapy through metformin first.

Minnesota patients who live near the borders (particularly the Twin Cities-to-Hudson, Wisconsin corridor) sometimes fill prescriptions across state lines to access lower pharmacy-specific pricing. This is legal. A valid Minnesota prescription can be filled at any licensed U.S. pharmacy, regardless of state. The savings from cross-border filling rarely exceed a few dollars for pioglitazone but can be more meaningful for higher-cost medications filled on the same trip.

Starting Pioglitazone in Minnesota: A Practical Checklist

Patients and prescribers can follow these steps to minimize cost and administrative friction when starting pioglitazone in Minnesota.

First, confirm the clinical indication and appropriate dose. Most patients start at 15 mg or 30 mg daily. Second, check insurance formulary status. For Medicaid patients, submit PA documentation early, as processing takes 24 to 72 hours in most cases. Third, if uninsured, compare prices across at least three pharmacies using a discount card platform. Fourth, order baseline labs (ALT, AST, BNP if heart failure risk factors exist) before the first dose. Fifth, schedule a follow-up at 8 to 12 weeks to assess glycemic response, weight trajectory, and edema.

Pioglitazone 30 mg once daily, filled as generic at a Minnesota retail pharmacy with a discount card, costs between $4 and $15 per month in 2026 [13].